Fate Therapeutics
FATE
78 hedge funds and large institutions have $216M invested in Fate Therapeutics in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 13 closing their positions.
475% more call options, than puts
Call options by funds: $46K | Put options by funds: $8K
115% more capital invested
Capital invested by funds: $101M → $216M (+$115M)
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
7.39% more ownership
Funds ownership: 61.35% → 68.75% (+7.4%)
5% more funds holding
Funds holding: 74 → 78 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$18.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.4M |
| 3 |
CC
Casdin Capital
New York
|
+$9.15M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.35M |
| 5 |
Millennium Management
New York
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.96M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$1.53M |
| 3 |
Goldman Sachs
New York
|
-$336K |
| 4 |
Renaissance Technologies
New York
|
-$333K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$318K |
FATE Hedge Fund Activity: Q4 2017 in Review
78 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2017, worth a combined $216M — up 115% from $101M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new FATE positions and 13 closed out — a net gain of 4 holders — while 29 added to existing stakes and 19 trimmed.
The largest buyer was Redmile Group, adding an estimated $18.1M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $8.96M sold.
- 78 institutional investors held Fate Therapeutics (FATE) as of Q4 2017, up from 74 in Q3 2017.
- Funds reported $216M of Fate Therapeutics stock for Q4 2017, up 115% quarter-over-quarter.
- 17 funds opened new Fate Therapeutics positions in Q4 2017 and 13 closed out, a net change of +4 holders.
- The largest Fate Therapeutics buyer in Q4 2017 was Redmile Group, an estimated $18.1M added.
- The largest Fate Therapeutics seller in Q4 2017 was EcoR1 Capital, an estimated $8.96M sold.
Based on aggregated 13F filings for Q4 2017.